Literature DB >> 32802248

Managing Rosacea in the Clinic: From Pathophysiology to Treatment-A Review of the Literature.

Sandra Marchese Johnson1,2,3, Andrew Berg1,2,3, Chelsea Barr1,2,3.   

Abstract

Rosacea is a chronic skin disease characterized by a waxing and waning course. It can encompass different symptoms including erythema, papules/pustules, telangiectasia, and phymata and sometimes secondary manifestations, such as itching, burning, or stinging. This article reviews recent changes in rosacea management. Discussion of relevant medical literature augmented with clinical expertise is also provided. Notably, while patients report that rosacea negatively impacts their emotional and overall well-being, they also tend to have low satisfaction with treatment and are prone to discontinuing therapy and/or using rosacea medications on an intermittent basis, thereby undermining treatment efficacy. Fortunately, the therapeutic armamentarium for rosacea is expanding, and experts now recommend a treatment approach that targets the presenting signs and/or symptoms, with the goal of achieving the greatest possible clearance. More so than in the past, several treatments can be used concurrently to best address the overall presentation of rosacea in an individual patient.
Copyright © 2020. Matrix Medical Communications. All rights reserved.

Entities:  

Keywords:  Rosacea; combination therapy; erythema; papulopustular lesions; targeted treatment

Year:  2020        PMID: 32802248      PMCID: PMC7384638     

Source DB:  PubMed          Journal:  J Clin Aesthet Dermatol        ISSN: 1941-2789


  38 in total

1.  Azelaic acid foam 15% in the treatment of papulopustular rosacea: a randomized, double-blind, vehicle-controlled study.

Authors:  Zoe Diana Draelos; Boni Elewski; Gerald Staedtler; Blanka Havlickova
Journal:  Cutis       Date:  2013-12

2.  Real-World Efficacy of Azelaic Acid 15% Gel for the Reduction of Inflammatory Lesions of Rosacea.

Authors:  P J Wirth; M H Henderson Berg; N Sadick
Journal:  Skin Therapy Lett       Date:  2017-11

3.  Ocular rosacea.

Authors:  Lenio S Alvarenga; Mark J Mannis
Journal:  Ocul Surf       Date:  2005-01       Impact factor: 5.033

4.  Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea.

Authors:  John E Wolf; Nabil Kerrouche; Stephanie Arsonnaud
Journal:  Cutis       Date:  2006-04

5.  Quality of Life in Individuals with Erythematotelangiectatic and Papulopustular Rosacea: Findings From a Web-based Survey.

Authors:  Joshua A Zeichner; Lawrence F Eichenfield; Steven R Feldman; J Scott Kasteler; Ilia L Ferrusi
Journal:  J Clin Aesthet Dermatol       Date:  2018-02-01

6.  Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea.

Authors:  Diane M Thiboutot; Alan B Fleischer; James Q Del Rosso; Klaus Graupe
Journal:  J Drugs Dermatol       Date:  2008-06       Impact factor: 2.114

Review 7.  Antibiotic use in acne vulgaris and rosacea: clinical considerations and resistance issues of significance to dermatologists.

Authors:  James Q Del Rosso; James J Leyden; Diane Thiboutot; Guy F Webster
Journal:  Cutis       Date:  2008-08

8.  The Burden of Illness of Erythematotelangiectatic Rosacea and Papulopustular Rosacea: Findings From a Web-based Survey.

Authors:  James Q Del Rosso; Emil A Tanghetti; Hilary E Baldwin; David A Rodriguez; Ilia L Ferrusi
Journal:  J Clin Aesthet Dermatol       Date:  2017-06-01

Review 9.  New insights into rosacea pathophysiology: a review of recent findings.

Authors:  Martin Steinhoff; Jürgen Schauber; James J Leyden
Journal:  J Am Acad Dermatol       Date:  2013-12       Impact factor: 11.527

10.  The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis.

Authors:  Kashif Siddiqui; Linda Stein Gold; Japinder Gill
Journal:  Springerplus       Date:  2016-07-22
View more
  1 in total

1.  Development of an animal model for rosacea‑like skin lesions caused by Demodex.

Authors:  Xue Luo; Nan Zhou; Lanxi Wu; Zhujun Wang; Jianhong Zhang; Xiuli Luan; Yang Luo
Journal:  Exp Ther Med       Date:  2022-08-08       Impact factor: 2.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.